Last reviewed · How we verify
Standard dose heparin
Standard dose heparin is a Anticoagulant Small molecule drug developed by San Filippo Neri General Hospital. It is currently FDA-approved for Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Acute coronary syndrome, Atrial fibrillation for stroke prevention. Also known as: 100 Ui/Kg bolus heparin.
Heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.
Standard dose heparin is used to treat conditions such as Venous Thromboembolic Event, Aneurysm, and Limb Ischemia, as well as to prevent complications in patients with Diffuse Large B Cell Lymphoma. It works by activating Antithrombin-III, a protein that inhibits blood clotting.
At a glance
| Generic name | Standard dose heparin |
|---|---|
| Also known as | 100 Ui/Kg bolus heparin |
| Sponsor | San Filippo Neri General Hospital |
| Drug class | Anticoagulant |
| Target | Antithrombin III (enhancer); indirect inhibition of thrombin and Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Heparin is an anticoagulant that works by binding to antithrombin III and dramatically increasing its ability to inactivate thrombin (Factor IIa) and Factor Xa. This prevents the formation of fibrin clots and the extension of existing clots. Standard (unfractionated) heparin has a rapid onset of action and is administered intravenously or subcutaneously.
Approved indications
- Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
- Acute coronary syndrome
- Atrial fibrillation for stroke prevention
- Prevention of thrombosis during cardiac surgery and extracorporeal circulation
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Thrombosis
- Osteoporosis (with prolonged use)
- Hyperkalemia
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Impact of Ligament of Marshall Resection on Atrial Fibrillation Occurrence in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Controlled Trial (NA)
- Dose for Reversal of Heparin After Cardiopulmonary Bypass (NA)
- Impact of CRRT on Serum Carnitine and Micronutrient Levels
- Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management (NA)
- A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant (PHASE1)
- Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard dose heparin CI brief — competitive landscape report
- Standard dose heparin updates RSS · CI watch RSS
- San Filippo Neri General Hospital portfolio CI
Frequently asked questions about Standard dose heparin
What is Standard dose heparin?
How does Standard dose heparin work?
What is Standard dose heparin used for?
Who makes Standard dose heparin?
Is Standard dose heparin also known as anything else?
What drug class is Standard dose heparin in?
What development phase is Standard dose heparin in?
What are the side effects of Standard dose heparin?
What does Standard dose heparin target?
Related
- Drug class: All Anticoagulant drugs
- Target: All drugs targeting Antithrombin III (enhancer); indirect inhibition of thrombin and Factor Xa
- Manufacturer: San Filippo Neri General Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Also known as: 100 Ui/Kg bolus heparin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing